Compare Davita Inc (DVA) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Prudential PLC — how do they compare? Davita Inc trades at $179.47 (market cap $11.38B), while Prudential PLC trades at $27.61 (market cap $34.02B). The key difference: Prudential PLC is far larger — about 3× Davita Inc's market cap, and Prudential PLC pays a 1.94% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | PUK | |
|---|---|---|
Market Cap | $11.38B | $34.02B |
Sector | Health | Financials |
52-Week High | $240.96 | $33.61 |
52-Week Low | $103.87 | $24.98 |
Enterprise Value | $24.10B | $35.46B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
Prudential PLC (PUK) trades at $28.22, down 0.21% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The stock shows strong fundamentals with a P/E of 8.92, net income margin of 14.52%, and ROE of 21.15%. Recent earnings beat expectations in Q4 2025, and cash flow from operations reached $3.61B in 2024. However, news of China taxing offshore insurance policies caused a recent sell-off, highlighting regulatory risks.
The outlook for PUK is mixed; solid profitability and low valuation metrics provide upside potential, supported by a 50% analyst buy rating. Key risks include exposure to Chinese regulatory changes and competitive pressures in Asia. Earnings growth and strategic focus on capital-light operations are catalysts, but investor sentiment remains cautious due to near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
